Calluna Pharma

As the year comes to a close, we're grateful to celebrate an exciting period of growth and achievement for Calluna Pharma. Here's a glimpse of our 2024 highlights: ➡️ Launched Calluna Pharma with a clear mission to transform the treatment of inflammatory and fibrotic diseases, supported by the successful completion of a €75 million Series A financing. ➡️ Strengthened our leadership team with key appointments: Margrethe Sørgaard joined as Senior Vice President of Clinical Operations and Pharmacovigilance, while Mark Altmeyer took on the role of Independent Chair of the Board. Additionally, we welcomed Mark Gaffney as CEO. ➡️Completed a successful Phase 1 clinical study for CAL101, our first-in-class therapeutic targeting fibrotic and fibro-inflammatory conditions. Beyond scientific advancements, we also got to share our mission and foster valuable connections via interviews published in leading trade publications and participation in key industry and investor events. As we reflect on these milestones, we’re energized for what lies ahead in 2025 and are thankful for our partners, team members, and supporters who have joined us on this journey! Wishing you all a joyful holiday season and a successful year ahead. 🌟

🩺𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗮 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Idiopathic Pulmonary Fibrosis (IPF) is a life-altering disease with limited treatment options. Calluna Pharma’s innovative approach with CAL101 aims to change the outlook for patients affected by this condition. Discover how Calluna Pharma, led by Chief Medical Officer and Co-Founder Jonas Hallén, is addressing this pressing medical challenge and preparing for Phase 2 clinical trials. Read the in-depth interview here: https://lnkd.in/dXuhRwUG The article series is produced in collaboration with the Norwegian health clusters Oslo Cancer Cluster, Norway Health Tech, Norwegian Smart Care Cluster, Biotech North and The Life Science Cluster.

Next week, our CEO Mark Gaffney, and CMO Jonas Hallén, are going to be in London for Jefferies London Healthcare Conference 2024 taking place November 19-21.   This year’s event marks the 15th anniversary of the largest healthcare-dedicated conference in Europe and will provide the opportunity for global healthcare companies, investors, and VCs to get together to discuss investment opportunities and current trends driving healthcare in the U.S. and internationally.    If you're going to be in London next week, reach out to our team to learn more about Calluna's pipeline of first-in-class therapeutic antibodies targeting inflammation and fibrosis: https://lnkd.in/ePihiB4T    #JefferiesHealthcare #Pharma #Healthcare 

Today, while at #BIOEurope, our CEO Mark Gaffney, caught up with Amy Brown from BiotechTV for an insightful interview on Calluna's journey and scientific vision.    Mark shared how Calluna was founded with the aim to develop innovative therapies for serious inflammatory and fibrotic diseases, and delved into the cutting-edge science behind our lead program, CAL101 – a first-in-class therapeutic that targets the S100A4 protein, a Damage Associated Molecular Pattern (DAMP) implicated in a range of serious diseases. During the interview, Mark also discussed our promising Phase 1 data in both healthy volunteers and patients with psoriasis, underscoring CAL101’s potential as a novel therapeutic. With Phase 2 trials planned in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis next year, we’re excited to advance this promising treatment for patients facing these debilitating conditions. A big thank you to BiotechTV and Amy Brown for highlighting our work at BIO-Europe. See the full interview: https://lnkd.in/gZUP8paq #Inflammation #Fibrosis #ClinicalTrial #Biotech

We’re #hiring a new SVP Discovery and Early Development in European Union. Apply today or share this post with your network.

Our CEO Mark Gaffney, and CMO Jonas Hallén are attending BIO-Europe in Stockholm, Sweden, next week, where the event marks 30 years of facilitating partnerships. Connect with our team at the event and register here: https://lnkd.in/dnuNZ2D Informa Connect See you there! #BIOEurope #Networking #Partnership 

We're excited to announce the successful completion of our Phase 1 clinical study for CAL101, Calluna’s lead drug candidate for the treatment of fibrotic and fibro-inflammatory diseases.   The first-in-human study demonstrated a favorable safety, pharmacokinetic and immunogenicity profile for CAL101 – a first-in-class mAb that targets S100A4, a DAMP protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis.   For a summary of key results, read the full press release here: https://bit.ly/3AcXNfL #Fibrosis #Sclerosis #ClinicalTrial #Biopharma #Immunology

📢 We are hiring! We are looking to strengthen our team. Are you passionate about finance, efficiency, and making an impact? Then you may be the person we are looking for. As a hands-on and strategic 𝗖𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗿, you will play a key role in the financial management of Calluna Pharma and its subsidiaries. Your responsibilities will include: ➖ Overseeing day-to-day financial operations, including accounts payable, payroll, and general ledger activities across all locations ➖ Ensuring compliance with local and international regulations, including financial reporting, tax filings and audits ➖ Conducting internal financial reporting, and providing financial analysis and models to support decision-making ➖ Leading and managing the budgeting and long-range forecasting processes Learn more about the role here ➡️ https://lnkd.in/drjaMXXz This is a great time to join our team – learn more about our work on our website and send your application to Renate.birkeli@callunapharma.com #Hiring #NewRole #Finance #Biotech

We’re delighted to unveil our newly updated website, now offering enhanced features and deeper insights into our work. Here’s what you can explore: 🔬The science behind developing our therapeutics – Targeting upstream innate immune amplifiers, our first-in-class therapeutics modulate a wide range of disease-associated signaling pathways while ensuring a favorable safety profile. 📊Pipeline overview – Get a detailed look at our development programs and upcoming milestones. 👥Meet our team, board, and investors – Learn more about the experts behind our company’s growth. 📰Latest news – Stay updated with our press releases and company developments. Vacancies – Explore available roles and become part of our mission. Visit our website to check out the new features and learn more about how we’re developing groundbreaking therapeutics targeting inflammation and fibrosis: https://lnkd.in/e37y2VKy #NewWebsite #LifeSciences #Innovation 

📢 New announcement! We are excited to announce two key appointments as we continue advancing our mission to combat inflammatory and fibrotic diseases. ➡Mark Gaffney has joined Calluna as Chief Executive Officer and member of the Board. Bringing over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, Mark will lead the team through our next phase of growth as we progress our product candidates into the clinic. ➡Mark Altmeyer has joined Calluna as Independent Chair of the Board. Having served on the boards and as an advisor to several pharma and biotech companies, Mark brings extensive leadership experience to the team and will be instrumental in helping shape Calluna’s future. Together, their expertise strengthens Calluna’s leadership and reinforces our commitment to revolutionize treatment options and improve patient outcomes. Welcome to the team both! Read the full press release: https://lnkd.in/eeSVcKVT #Leadership #ExecutiveAppointment #PressRelease #LifeSciences #CEO #BoardChair